Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Biotheus Completes $100 Million Funding for Biologic Drugs

publication date: Mar 3, 2021

Biotheus, a Guangdong biotech, completed a $100 million Series D financing co-led by General Atlantic and IDG Capital. Founded in 2018, Biotheus is developing a broad portfolio of me-better/novel drugs focused on immuno-oncology and metabolic diseases. So far, the company has built a portfolio of 10 innovative monoclonal and multispecific antibodies, with two bispecific antibodies in Phase I trials for cancer and a third IND application under review in China. Biotheus plans to out-license late-stage clinical and commercialization activities to global partners. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital